S
#HealthcareInnovation #TemperatureControl #PatientSafety
www.streetinsider.com
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026.